World-first guidelines for children with common inherited nerve disorder: Paediatric neurologists and allied health clinicians have developed world-first clinical practice guidelines for children with Charcot-Marie-Tooth disease (CMT), the most common childhood inherited nerve disorder.
Murdoch Children’s Research Institute (MCRI) research associate Dr Eppie Yiu and University of Sydney Professor Joshua Burns led an international effort to produce the guidelines, which address the management of clinical problems experienced by children with CMT and related neuropathies (weakness, numbness and pain from nerve damage), and advocates for improved access to multidisciplinary care.
CMT is a lifelong degenerative condition that causes damage to the nerves, muscle weakness, sensory problems, difficulty walking, foot deformity and associated pain, which usually start during childhood and progress over time. Although there is currently no cure, people with CMT can use a variety of therapies and strategies to help manage their symptoms.
The disease is the most common inherited nerve disorder. Yet until now, there were no guidelines to help patients manage their condition. To address this need, Dr Yiu, Professor Burns and their team formed the Paediatric CMT Best Practice Guidelines Consortium, involving clinicians from Australia, Belgium, Canada, Croatia, the US, the Czech Republic, Italy and the UK.
“The aim was to develop evidence and consensus-based recommendations for the clinical management of children and adolescents with CMT,” Dr Yiu said.
Dr Yiu said the guidelines would promote optimal, standardised care for children with CMT globally, improve access to multidisciplinary care, such as via the National Disability Insurance Scheme (NDIS), and were critical for clinical trial readiness.
To develop the guidelines, the international panel of clinicians conducted a series of systematic reviews covering 10 clinical questions and evaluated the body of literature on CMT disease management. The panel then formulated recommendations based on these reviews.
The guidelines, published in the Journal of Neurology, Neurosurgery and Psychiatry, include evidence and consensus-based recommendations for the management of muscle weakness, balance and mobility impairment, sensory symptoms, muscle cramps, impaired upper limb function, respiratory impairment, joint movement and non-surgical management of joint deformity.
Dr Yiu said she hoped the recommendations would be disseminated and implemented across multiple healthcare settings around the world to benefit children and young people with CMT.
“The guidelines are important for a range of medical and allied health clinicians who provide care to children with CMT, including neurologists, rehabilitation specialists, physiotherapists, occupational therapists, clinical nurse specialists and genetic counsellors,” she said.
Clinicians from The Royal Children’s Hospital, University of Melbourne, The Children’s Hospital at Westmead, Sydney Children’s Hospital, Randwick, UNSW Sydney, Macquarie University and Concord Hospital, The Children’s Hospital of Philadelphia, University of Antwerp, Stanford and the University of Pennsylvania also took part in the review.
Publication: Eppie M Yiu, Paula Bray, Jonathan Baets, Steven K Baker, Nina Barisic, Katy de Valle, Timothy Estilow, Michelle A Farrar, Richard S Finkel, Jana Haberlová, Rachel A Kennedy, Isabella Moroni, Garth A Nicholson, Sindhu Ramchandren, Mary M Reilly, Kristy Rose, Michael E Shy, Carly E Siskind, Sabrina W Yum, Manoj P Menezes, Monique M Ryan, Joshua Burns. ‘Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease,’ Journal of Neurology, Neurosurgery & Psychiatry. DOI: 10.1136/jnnp-2021-328483
This work was supported by the National Health and Medical Research Council of Australia (NHMRC, National Centre for Research Excellence in Neuromuscular Disorders, number 1031893), and the NHMRC–European Union Collaborative Research Grant Scheme (Improving health outcomes for chronic rare diseases and reducing inequality of care, number 1055131, FP7 Rare Best Practice). EMY was supported by an NHMRC early career fellowship (APP1073323) during the course of this project. J Baets receives grant support from the Association Belge contre les Maladies Neuromusculaire (ABMM) – Aide à la Recherche ASBL (2017-2018/05), the EU FP7/2007-2013 under grant agreement number 2012-305121 (NEUROMICS) and the EU Horizon 2020 program (Solve-RD under grant agreement No 779257). J Baets is supported by a Senior Clinical Researcher mandate of the Research Fund—Flanders (FWO) under grant agreement number 1805021N. MAF receives grant support from the NHMRC (APP1194940). IM has previously received grant support from the CMT Rete (Italy). RSF receives grant support from the NIH and the CMT Association. MES receives grant support from the NIH (U54NS065712). SWY receives grant support from the Muscular Dystrophy Association.
*The content of this communication is the sole responsibility of MCRI and does not reflect the views of the NHMRC.
- Teachers strikes: Fear of disruption to patient care - 7th February 2023
- Low-grade inflammation may cause arterial stiffness in healthy adolescents - 7th February 2023
- New study refines precision of medical needles in surgical simulation - 7th February 2023